Medicines Co's hemostasis drug effective in late: stage study
(Reuters) - Medicines Co said its experimental drug to help stop bleeding during surgery was found effective in a late-stage study, sending its shares up more than 2 percent.
The drug, which met all the main and secondary goals, is a dry powder topical formulation that Medicines Co acquired through its purchase of Profibrix in June.
The drug, Fibrocaps, was tested on 719 patients in four surgical indications of spinal surgery, hepatic resection, soft tissue dissection and vascular surgery.
Shares of the company rose 2.4 percent to $32.24 in after-hours trading on Monday.
(Reporting by Zeba Siddiqui in Bangalore; Editing by Saumyadeb Chakrabarty)
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis |
- California passes 'yes-means-yes' campus sexual assault bill
- In town halls, U.S. lawmakers hear voter anger over illegal migrants |
- IBM launches Watson system for research, hopes for breakthroughs
- Family of instructor killed at Arizona gun range does not blame girl